- Home
- BMRA vs LGVN Comparison
BMRA vs LGVN Comparison
Compare BMRA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- LGVN
- Stock Information
- Founded
- BMRA 1971
- LGVN 2014
- Country
- BMRA United States
- LGVN United States
- Employees
- BMRA N/A
- LGVN N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BMRA Health Care
- LGVN Health Care
- Exchange
- BMRA Nasdaq
- LGVN Nasdaq
- Market Cap
- BMRA 8.1M
- LGVN 23.4M
- IPO Year
- BMRA N/A
- LGVN 2021
- Fundamental
- Price
- BMRA $3.09
- LGVN $1.31
- Analyst Decision
- BMRA
- LGVN Strong Buy
- Analyst Count
- BMRA 0
- LGVN 3
- Target Price
- BMRA N/A
- LGVN $8.67
- AVG Volume (30 Days)
- BMRA 26.1K
- LGVN 146.0K
- Earning Date
- BMRA 04-14-2025
- LGVN 08-13-2025
- Dividend Yield
- BMRA N/A
- LGVN N/A
- EPS Growth
- BMRA N/A
- LGVN N/A
- EPS
- BMRA N/A
- LGVN N/A
- Revenue
- BMRA $5,678,000.00
- LGVN $2,225,000.00
- Revenue This Year
- BMRA N/A
- LGVN N/A
- Revenue Next Year
- BMRA N/A
- LGVN $51.48
- P/E Ratio
- BMRA N/A
- LGVN N/A
- Revenue Growth
- BMRA 5.01
- LGVN 127.50
- 52 Week Low
- BMRA $1.93
- LGVN $1.14
- 52 Week High
- BMRA $10.16
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- BMRA 45.39
- LGVN 50.13
- Support Level
- BMRA $3.03
- LGVN $1.15
- Resistance Level
- BMRA $3.44
- LGVN $1.32
- Average True Range (ATR)
- BMRA 0.19
- LGVN 0.09
- MACD
- BMRA 0.01
- LGVN 0.01
- Stochastic Oscillator
- BMRA 43.24
- LGVN 45.31
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.